We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Penn and Kroin first described the benefits reporting the treatment of six patients with severe continuing spasticity and spasms resulting from spinal injury or multiple sclerosis. Baclofen is hydrophilic and crosses the blood-brain barrier poorly. Spinal intrathecal administration bypasses the blood-brain barrier, allowing effective treatment of spasticity with a dose range that is 100 to 1000 times smaller than that required for oral treatment. The plasma levels of baclofen in patients undergoing intrathecal infusion have been found to be vanishingly low. Intrathecal baclofen (ITB) reduces spasticity, as clinically assessed using the Ashworth scale. Flexion or extension spasms, more common in the lower limbs, may occur spontaneously or in response to cutaneous stimuli in association with spasticity. The threshold of the electrically induced flexion reflex in the lower limb has been found to be reduced in spinal spasticity and the response amplitude to be increased.
Edited by
Michael Selzer, University of Pennsylvania,Stephanie Clarke, Université de Lausanne, Switzerland,Leonardo Cohen, National Institute of Mental Health, Bethesda, Maryland,Pamela Duncan, University of Florida,Fred Gage, Salk Institute for Biological Studies, San Diego
Cerebral palsy (CP) is the common diagnostic cause of the upper motor neurone (UMN) syndrome in childhood, a syndrome characterised by positive features and negative features. In CP, spasticity has both neurophysiological and musculoskeletal components. While traditional clinical evaluation of spasticity include symptoms and signs together with examination of muscle tone, range of movement (ROM), and functional impact, assessment also include validated quantitative and qualitative instruments. Oral medications affect muscles involved to varying degrees of spasticity, including both the target muscles and those for which loss of tone and/or function is undesirable. Combination treatment, such as botulinum toxin A (BoNT-A) or orthopaedic surgery, physical therapy and oral baclofen are used in clinical practice with anecdotal benefit, but the results of further scientific studies to prove the extra benefit are awaited. While selective dorsal rhizotomy (SDR) reduces spasticity, it has no effect on selective motor control (SMC), balance or fixed deformities.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.